NUTLEY, N.J., July 6 /PRNewswire-FirstCall/ -- Nephrologists attending the upcoming 43rd European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) congress in Glasgow, Scotland, July 15-18, will be able to hear a range of study results from Roche’s robust clinical development program for its investigational anti-anemia drug, C.E.R.A. (Continuous Erythropoietin Receptor Activator).
Among the highlights will be the first public presentation of data from the C.E.R.A. Phase III clinical development program -- the largest of its kind -- with results from the maintenance studies in dialysis patients.
C.E.R.A. Presentations Author: N. Levin Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every two weeks or once monthly maintains hemoglobin (Hb) levels in patients with chronic kidney disease(CKD) on Dialysis. Sunday, July 16, 2006 Oral Session: 13:45 - 15:15; Hall 1 Poster ID: SO23 Author: W. Sulowicz Subcutaneous (SC) C.E.R.A. (continuous erythropoietin receptor activator) administered once every two weeks or once monthly maintains hemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on Dialysis. Sunday, July 16, 2006 Poster Session: 08:00 - 16:00; Poster Area, Hall 4 Poster ID: SP424 Author: B. Canaud Intravenous (IV) C.E.R.A. (continuous erythropoietin receptor activator) administered once every two weeks maintains stable hemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis. Sunday, July 16, 2006 Poster Session: 08:00 - 16:00; Poster Area, Hall 4 Poster ID: SP425 Author: M. Brandt Different receptor binding activity of C.E.R.A. (continuous erythropoietin receptor activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells. Sunday, July 16, 2006 Oral Session: 13:45 - 15:15; Hall 1 Poster ID: SO18
Interested journalists may view the titles of ERA-EDTA abstracts selected for presentation, as well as the meeting schedule online at http://www.eraedta2006.org/fp2006.htm .
Roche
CONTACT: Shelley Rosenstock, Roche, +1-973-562-2373,shelley.rosenstock@roche.com; Diana Scott, MS&L, +1-212-468-4271,diana.scott@mslpr.com
Web site: http://www.eraedta2006.org/fp2006.htm/
